Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELIVER-02 dual DART treatment with latency reversal in people with HIV on ART
PACTR202511728273171Phase 1Not yet recruiting
- Start
- Jan 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MGD020, MGD014 and vorinostat in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoints: Occurrence of at least one grade 3 or higher related adverse event and Completion of full study treatment. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
MGD020MGD014vorinostat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202511728273171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511728273171.